Physicians’ Education Resource® Hosts the 38th Annual Miami Breast Cancer Conference® in Expanded, Interactive Virtual Meeting Format
24.2.2021 21:12:00 EET | Business Wire | Press release
As the leading go-to resource for continuing medical education (CME), Physicians’ Education Resource®, LLC, (PER®), has been committed to improving the care for patients with breast cancer by educating the treatment team for nearly four decades. This commitment is more than professional, but also deeply personal. This annual marquee CME conference has been family-led since the beginning and continues to incorporate that family spirit into 2021 in the virtual setting.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005893/en/
Traditionally hosted as a live marquee meeting, this year’s 38th Annual Miami Breast Cancer Conference® has transformed into a live-broadcast virtual and interactive experience leveraging new online meeting technologies. This year, the conference is more than Miami, and will bring the educational experience directly to health care professionals online.
For 37 years, the historic multidisciplinary Miami Breast Cancer Conference® has been a family-led annual meeting. By combining the conference’s legacy with the Hennessy family spirit and commitment infused into the DNA of MJH Life Sciences™, the parent company of PER®, this year’s meeting will continue to focus on improving the care of patients with breast cancer. The annual conference has become a landmark meeting that serves as the go-to resource for health care professionals to learn about the most important advancements in breast cancer treatment and how to translate these into clinical care.
“In its 38th year, whether this is your first time or your 31st time attending, PER® welcomes you as part of the Miami Breast Cancer Conference® family,” said Phil Talamo, CHCP, president of PER®. “Our community is full of dedicated oncologists, surgeons, pathologists, nurses, and more who are committed to elevating patient care. We know that it takes more than a team to treat breast cancer – it takes a family. During this year’s conference, we will virtually come together with a shared purpose of driving contemporary patient care using strategies that you hear on Friday and use on Monday.”
This year’s 38th Annual Miami Breast Cancer Conference® will continue this tradition increase the use innovative virtual technology to deliver the robust educational programming and top-notch presentations for which this conference is known for. New in 2021, PER® has expanded its afternoon programming to the full healthcare team with additional tracks on pathology, radiation oncology, and oncology nursing. To accommodate its international learners in European time zones, an international track will also be offered. This will broaden the Conference’s impact and bring vital members of the treatment team into the Miami Breast Cancer Conference family, united in the approach to improve the care of patients with breast cancer.
Additionally, this year’s expanded virtual program will feature world-class tumor board panels, multidisciplinary meet-the-expert sessions, case discussions, poster sessions, a video surgical library, lively Medical Crossfire® exchanges, and more. Included among the many important clinical and practical topics on the agenda are novel therapeutic targets, contemporary management issues, oncology care in the COVID-19 era, practical application of genomics, precision medicine, and more.
For more information and to register, click here.
About Physicians’ Education Resource® (PER®)
Since 1995, PER® has been dedicated to advancing cancer care through professional education and now advances patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER® initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas. Although it is expanding into topics outside of oncology, PER® stands as the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. PER® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is a brand of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005893/en/
Contact information
PER® Media
Contact
Alexandra Ventura, 609-716-7777
aventura@mjhlifesciences.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Oral‑B Announces The Big Rethink 2026 , Launching One of Europe’s Largest Disability‑Focused Oral Health Studies13.5.2026 10:06:00 EEST | Press release
Oral‑B today announces The Big Rethink 2026, the next evolution of its flagship oral health inclusion programme, developed in partnership with the International Association for Disability and Oral Health (iADH). The new phase introduces Project Steady, one of Europe’s largest real‑world studies exploring oral care experiences among people with disabilities, their carers and dental professionals. The programme aims to reduce everyday barriers to oral care through inclusive design, evidence-based research and professional education. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511175864/en/ Oral B Announces The Big Rethink 2026, Launching One of Europe’s Largest Disability Focused Oral Health Studies Oral health for Whole-Body Health Since its launch in 2022, The Big Rethink has been grounded in a clear belief: oral health is fundamental to whole‑body health, confidence and quality of life. For people with disabilities, b
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results13.5.2026 09:38:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was partially mitigated by Growth and Launch Products. On a Core basis, Revenue decreased by 2.6% at Constant Exchange Rate (CER). Core Operating Profit increased by 0.8% YoY at AER and declined by 0.9% at CER, protected by OPEX savings, while still investing for growth. Reported Operating Profit increased by 19.3% YoY at AER, also reflecting a step-down in amortization expenses for VYVANSE and lower restructuring expenses. Core EPS increased by 5.2% YoY at AER and by 3.1% at CER, while reported EPS increased by 78.1% YoY. Adjusted Fre
Allianz Delivers Record Operating Profit in Strong Start to 202613.5.2026 08:20:00 EEST | Press release
1Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512320157/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Total business volume at 53.0 billion euros, an internal growth of 3.5 percent1. This was driven by a strong development in Property-Casualty and Asset Management Operating profit rises 6.6 percent and reaches a record level of 4.5 billion euros Shareholders’ core net income advances by 48.4 percent to 3.8 billion euros, impacted by the sale of the stakes in our Indian Joint Ventures. Underlying growth, which adjusts for the sale effects and offsetting measures, is strong at 7 percent2Core earnings per share grow 50.7 percent and reach 9.96 euros. Adjusted for the above-mentioned effects, underlying growth is excellent at 9 percent 2Annualized core RoE at 24.2 percent, underlying level very strong at 18 percent 2Solvency IIratio3 increases by 2 percentage points to 221 percent4. Capital generation was st
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca13.5.2026 08:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their three-year licensing of K Pro – Owkin’s AI Scientist for biopharma decision making. K Pro brings multimodal data and specialized biological agentic AI to each step of the value chain. Under the three-year licensing agreement, Owkin will lead the end-to-end development of AI agents to run on K Pro, integrated within AstraZeneca’s IT infrastructure and decision workflows. The new agents' functionality is intended to help AstraZeneca’s decision-making teams access timely, data-rich insights for complex competitive intelligence questions, reducing reliance on manual analysis within established governance, security, and enterprise standards. "At Owkin, we believe the future of the pharmaceutical industry is agentic," said Thomas Clozel, CEO and co-founder of Owkin. "Our exper
Abu Dhabi's Phoenix Group Partners with DC Max to Unlock $8 Billion European AI Data Center Opportunity, with Lyon, France as First Deployment13.5.2026 08:00:00 EEST | Press release
Phoenix Group PLC (ADX: PHX), an IHC portfolio company and global digital infrastructure operator, today announced a strategic partnership with DC Max to develop its first European AI data center, an 18MW facility in Lyon, France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512531777/en/ From left to right: Matthias Luecker, Chairman of DC Max, and Munaf Ali, Co-Founder and Group CEO of Phoenix Group, during the signing ceremony for the strategic partnership between Phoenix Group and DC Max to launch a European AI infrastructure platform anchored by the company’s first deployment in Lyon, France. (Photo: AETOSWire) The project is the inaugural deployment of Phoenix's European Data Center Platform, a scalable framework targeting over 1GW of combined AI and HPC capacity across Europe and the GCC. Phoenix sees this move as a direct extension of the UAE’s national AI ambition, an Abu Dhabi-headquartered company bringing it
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
